- Company
- MOHW: “Cancer Committee to be rescheduled in March”
- by Eo, Yun-Ho Mar 6, 2020 06:06am
- The Cancer Deliberation Committee meeting initially canceled due to COVID-19 outbreak would be rescheduled again soon. Pharmaceutical industry sources reported Korea’s Ministry of Health and Welfare (MOHW) plans to review some of drugs on paper, but to conduct vis-à-vis review on significant drugs applying for reimbursement expan
- Company
- MFDS clears varicella vaccine license for GC Pharma
- by Lee, Seok-Jun Mar 6, 2020 06:06am
- GC Pharma announced on Mar. 4 its chickenpox vaccine ‘Varycella’ injection has recently won an item license from Ministry of Food and Drug Safety for the Korean market. Like other existing chickenpox vaccines, the company stated Varycella is a live attenuated varicella virus vaccine. The Korean company was able to push up the prod
- Company
- Industry fears sales ban as NDMA risk in metformin rekindled
- by Chon, Seung-Hyun Mar 6, 2020 06:06am
- The risk of impurity found in metformin could resurface due to another warning from the U.S.-based private research firm. The pharmaceutical industry’s concern deepens as the same research firm that warned about ranitidine risk last year published the metformin analytic data. Already pharmaceutical companies fear global health authoritie
- Company
- 86% of generics for erectile dysfunction are domestic
- by Chon, Seung-Hyun Mar 5, 2020 06:33am
- The sales rate of generic products developed in Korea in the erectile dysfunction market is very high. Hanmi pharm's Palpal is one of hottest items, and Chong Kun Dang's Cendom continued to rise. Domestically developed drugs account for 86% of the erectile dysfunction drug market, and the influence of domestic products is expanding. According
- Company
- Janssen Korea breaks through KRW 300 bln for the first time
- by An, Kyung-Jin Mar 5, 2020 06:33am
- Janssen Korea broke through the 300 billion won-line in Korea for the first time. Leveraged by outstanding performance of star products like Remicade, Simponi and Stelara, the global pharmaceutical company manifested impressive sales revenue and operating profit. According to performance data of last fourth quarter provided by Yuhan on
- Company
- Boryung Bio releases 'self-sufficient' quadrivalent vaccine
- by An, Kyung-Jin Mar 5, 2020 06:33am
- On Mar. 2, Boryung Biopharma announced the release of ‘Boryung DTaP-IPV Vaccine’ for infants and children. ‘Boryung DTaP-IPV Vaccine’ is a quadrivalent vaccine consisting of DTaP vaccines preventing diphtheria, tetanus and pertussis and inactivated polio vaccine (IPV) against poliomyelitis. Total six doses is required when administer
- Company
- BMS-Celgene merger restructures Korean office
- by Eo, Yun-Ho Mar 4, 2020 06:27am
- The basic frame of Bristol-Myers Squibb (BMS) and Celgene’s merger company has been unveiled. Recently, BMS presented a newly formed division and appointed the head of Business Unit for the merger. The Commercial Business Unit, including marketing and sales, would undergo the biggest change. BMS has decided to integrate BMS’ existi
- Company
- Whan In has signed domestic monopoly rights of 'Cariprazine'
- by Jung, Hye-Jin Mar 4, 2020 06:27am
- Whan In Pharm (CEO Won-bum Lee) announced on the 2nd that it has signed an exclusive contract to introduce Cariprazine, a schizophrenic drug from Gedeon Richter, Hungary. Under this contract, Whan In Pharm is responsible for commercializing, distributing and selling products such as domestic clinical trials and product approval of Caripraz
- Company
- In the aftermath of the COVID-19, the BA test was disrupted
- by Chon, Seung-Hyun Mar 4, 2020 06:27am
- COVID-19 infections have also influenced the generic development strategies of pharmaceutical companies. Due to the risk of infection with COVID-19, the bioequivalence task of medical institutions has been disrupted. This is an embarrassing situation for pharmaceutical companies that are conducting bioequivalence tests to reduce drug prices a
- Company
- Eisai’s low-dose Pariet passed by general hospital DCs
- by Eo, Yun-Ho Mar 3, 2020 06:10am
- Low-dose Pariet is landing on general hospital prescription code. Pharmaceutical industry source reported Drug Committees in Severance Hospital, Samsung Medical Center, and Korea University Guro Hospital cleared proton pump inhibitor (PPI) Pariet 5 mg tablet (rabeprazole sodium), which received National Health Insurance reimbursement in
